<DOC>
	<DOCNO>NCT01472640</DOCNO>
	<brief_summary>Type 2 diabetes ( T2D ) major risk factor chronic heart failure ( CHF ) . Glycemic control patient combination T2D CHF complicate currently available treatment proven inadequate clinical trial . Objectives To investigate effect Liraglutide compare placebo leave ventricular ejection fraction ( LVEF ) CHF patient without T2D . Multicenter , randomize , double blind study 240 patient document systolic CHF ( 50 % T2DM ) randomise . The effect Liraglutide leave ventricular systolic diastolic function evaluate advanced echocardiography Primary outcome parameter change LVEF visit 1 week 24 .</brief_summary>
	<brief_title>The Effect Liraglutide Left Ventricular Function Chronic Heart Failure Patients With Without Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Background The number patient diabetes Denmark double precede 10-years period increase 271.000 individual ( 5 % population ) . T2D major risk factor CHF CHF per se associate insulin resistance , thus T2D CHF often co-exists , associate markedly impaired prognosis . Glycemic control patient combination T2D CHF complicate currently available treatment proven inadequate clinical trial . Therefore , new treatment modality hyperglycaemia CHF warrant . Glucagon-like peptide 1 ( GLP-1 ) naturally exist hormone , secrete incretine system . A beneficial effect GLP-1 cardiac function recently suggest small clinical study , demonstrate improve left ventricular ejection fraction ( LVEF ) diabetic non-diabetic patient . Liraglutide ( Victoza® ) GLP-1-analogue develop treatment T2D . However , impact Liraglutide cardiac function currently investigation . Objectives Primary objective : To investigate effect Liraglutide 1.8 mg daily compare placebo LVEF CHF patient without T2D 24 week treatment . Secondary objective : To investigate effect Liraglutide 1.8 mg daily compare placebo leave ventricular diastolic function , plasma level NT-proBNP , symptom heart failure quality life 24 week treatment . Design Multicenter , randomize , double blind study evaluate impact 24 week treatment Liraglutide versus placebo cardiac function CHF patient without T2D . Population A total 240 patient document systolic CHF ( 50 % T2DM ) randomise . The effect Liraglutide leave ventricular systolic diastolic function evaluate advanced echocardiography use 2D , 3D , tissue Doppler imaging . Primary outcome parameter change LVEF visit 1 week 24 Perspectives Irrespective outcome , study contribute essential information regard treatment CHF . Potentially Liraglutide improve heart function substantially , thus change prognosis CHF-patients worldwide . Detailed statistical analysis plan Outcomes Primary objective To investigate effect liraglutide uptitrated maximum 1.8 mg daily compare placebo 24 week difference leave ventricular ejection fraction ( LVEF ) baseline follow-up chronic heart failure patient ( CHF ) patient without type 2 diabetes ( T2D ) . Secondary objective To investigate effect liraglutide compare placebo term change baseline follow-up 1 . Left ventricular contractile function measure I . Global longitudinal strain speckle track II . Mitral plane systolic annular max velocity TDI ( ' , average six point ) 2 . Left ventricular end-systolic volume ( LVESV ) end-diastolic volume ( LVEDV ) 3 . Grade diastolic function 4 . Functional capacity measure 6-minute walk test ( 6MWT ) 5 . Plasma NT-proBNP level 6 . Blood pressure 7 . Quality life evaluate MLHF questionnaire 8 . Hospitalisations due cardiovascular disease 9 . All-cause mortality ( confirmed Central Personal Register ) The investigator blind liraglutide versus placebo assess outcome . Investigators analyse data treatment group A B , primary analysis perform approve data unblinded . The manage committee contribute preparation analysis plan also approve . Sample size Primary objective The primary outcome parameter change LVEF visit 1 week 24 . A total 241 patient randomise allow approximately 20 % randomise patient major protocol deviation withdrawal . With 90 % power two-sided significance level 0.05 , sample size analysis estimate study detect difference 2.5 % LVEF absolute value . The power analysis base standard deviation 6 % delta EF ( absolute unit ) . An absolute difference 2.5 % change baseline two treatment group base clinical relevance determine study impact ACE inhibitor betablockers LVEF . These key outcome ACE-inhibitor key betablocker trial show relative risk reduction outcome approximately 25 - 30 % treatment . Stratification The randomisation perform use two stratification variable : Gender ( female/male ) diabetes ( yes/no ) . Data management Data collect real time custom-made web base electronic case record form ( eCRF ) host external data management unit Aarhus University . In compliance GCP , study manual collection endpoint procedure develop , quality assurance relevant instrument collect sponsor trial master file . Data adverse event assess investigator clinically significant , include abnormal laboratory value , collect record standardised form contact . These data report relevant authority accordance current legislation ICH-GCP guideline . An unblinded data monitoring committee , consist independent cardiologist endocrinologist , establish evaluate event study conduct . Statistical analysis Data analyse accord intention-to-treat principle . Sites encourage obtain final measure primary endpoint soon possible patient terminate study medication prematurely . Multiple imputation method apply handle miss data primary endpoint . A per protocol analysis also perform . The per protocol population consist patient complete study document valid baseline , 24 week assessment primary objective major protocol deviation . Data analyse difference baseline follow-up . Normally distributed variable present mean ± standard deviation ( SD ) , whereas non-normally distributed variable present median [ range ] . Comparisons group perform unpaired Student 's t-test ANOVA data normally distribute . Mann-Whitney U test Kruskal-Wallis one-way analysis use non-normally distributed data . Subgroup analyse make respect : presence diabetes , cause heart failure ( ischemic/non-ischemic ) , body mass index , NYHA-class , LVEF above/below mean , atrial fibrillation . Linear regression use study correlation outcome parameter baseline patient characteristic . Categorical variable present number percentage ; Chi-square-test use compare group categorical variable . P-values &lt; 0.05 consider statistically significant . All calculation perform use commercially available program ( SPSS Windows Mac , version 22.0 ) . Population handle miss data Most statistical method fail handle case miss value , may introduce bias affect representativeness result . Imputation preserve case replace miss data probable value base available information data set . Once miss value impute , data set analyse use standard technique complete data . Imputation method apply handle miss data primary endpoint . Characteristics patient baseline A description baseline characteristic intervention group present . Discrete variable summarise frequency percentage . Percentages calculate accord total number patient particular group . Continuous variable summarise use standard measure central tendency dispersion use either mean ± SD data normal distribution median interquartile range non-normally distribute data . Outline figure table The first figure consort flow chart respectively GLP-1 versus placebo . The first table describe baseline characteristic . Follow-up data describe table .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Able understand write patient information give inform consent CHF , NYHAclass I , II III visit 0 LVEF ≤45 % Age 30 85 ( inclusive ) Stable pharmacological treatment heart failure accord ESC guideline last 3 month prior randomisation ( visit 1 ) For patient diabetes exclusively : T2D ( WHO criteria ) , diagnose least 3 month prior visit 0 Patients diabetes must either untreated treat one oral antidiabetic drug treat human NPHinsulin longacting insulin analogue , alone combination oral drug Stable optimal dose anti diabetic treatment 30 day prior randomisation ( visit 1 ) Myocardial infarction ( MI ) , unstable angina coronary revascularization within last three month prior visit 1 Hospitalisation due incompensated heart disease within 30 day prior randomisation ( visit 1 ) CHF ( NYHA class IV ) ECG suggestive malign ventricular arrhythmia visit 0 Type 1 diabetes HbA1c &gt; 10 % measure visit 0 Use GLP1 receptor agonist ( Exenatide , Liraglutide ) glitazones , pramlintide DPPIV inhibitor within 30 day prior randomisation ( visit 1 ) Known suspected hypersensitivity trial product relate product Alcohol/drug abuse Pregnant nursing woman Fertile woman use chemical ( tablet/pill , depot injection progesterone , subdermal gestagen implantation , hormonal vaginal ring transdermal hormonal patch ) mechanical ( spiral ) contraceptives Cancer unless complete remission ≥5 year Liver disease elevate plasma alanine aminotransferase ( ALT ) three time upper limit normal ( measured visit 0 possibility one repeat analysis within week , last measure value conclusive ) Inflammatory bowel disease Acute chronic pancreatitis Gastroparesis Compromised kidney function ( eGFR &lt; 30 ml/min ) , dialysis kidney transplantation History thyroidea adenoma carcinoma Severely elevate blood pressure ( systolic &gt; 180 mmHg and/or diastolic &gt; 105 mmHg ) Other concomitant disease treatment accord investigator 's assessment make patient unsuitable study participation Simultaneous participation clinical intervention trial Receipt investigational drug 30 day prior visit 0</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>CHF , Diabetes ; Liraglutid , Ecco</keyword>
</DOC>